Showing 961-970 of 9107 results for "".
All Things Psoriasis With Dr. April Armstrong
https://practicaldermatology.com/series/the-practical-dermatology-podcast/all-things-psoriasis-with-dr-april-armstrong/36135/The latest news and updates, plus April W. Armstrong, MD, MPH, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the current state of psoriasis treatments, what's in the pipeline, her experience in leadership positions for multiple psoriasis organizations, and more.Phio Pharmaceuticals Takes Aim at Skin Cancer
https://practicaldermatology.com/series/c-suite-chats/phio-pharmaceuticals-takes-aim-skin-cancer/24316/In the first episode of Practical Dermatology's C-Suite Chats, Robert Bitterman, CEO of Phio Pharmaceuticals, discusses the company's patented INTASYL technology. Learn more about this platform for creating and delivering uniquely modified siRNA compounds to treat cancer.DermWireTV: Atopic Dermatitis Guidelines, Derm Devices, and New Research
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-atopic-dermatitis-guidelines-derm-devices-and-new-research/20234/In this episode of DermWire TV, we report on the new atopic dermatitis guidelines, the long-term safety of upadacitinib, and novel energy-based dermatology devices. From the new at-home treatment for molluscum contagiosum to the discovery of genetic factors in early-onset Merkel cell carcinoma, thisFDA Approves Roflumilast for Seborrheic Dermatitis in Young Patients
https://practicaldermatology.com/topics/other-dermatitis/fda-approves-roflumilast-for-seborrheic-dermatitis-in-young-patients/20230/Patrick Burnett, MD, PhD, chief medical officer of Arcutis Biotherapeutics, talks with Practical Dermatology® about the first new treatment for seborrheic dermatitis in more than 20 years, their newly approved ZORYVE (roflumilast)Topical Foam, 0.3% for use in patients aged 9 years or older.Clinical Conversations: The Data for JAK Inhibitors in AD
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-the-data-for-jak-inhibitors-in-ad/20105/JAK inhibitors represent a new therapeutic class for the treatment of atopic dermatitis. Find out what the data show about their efficacy and tolerability in a conversation between Brad Glick, DO and Raj Chovatiya, MD. Discover how these drugs can fit into the treatment plan and how these experts diPrescribing Biologics: Don't Be Afraid
https://practicaldermatology.com/conferences/aad-summer-2021/prescribing-biologics-dont-be-afraid/19969/Dermatologists have access to a growing armamentarium of safe and effective systemic therapies, but many physicians and patients are still hesitant to use them. Neal Bhatia, MD discusses the importance of prescribing biologics to patients with moderate to severe psoriasis to offer a safe and efficacDermWireTV: GlobalSkin, ILDS Collab; New approach with Tafinlar; Equity in Telehealth; Dupixent pen
https://practicaldermatology.com/topics/practice-management/dermwiretv-globalskin-ilds-collab-new-approach-with-tafinlar-equity-in-telehealth-dupixent-pen/19952/A data analysis presented at the 2021 American Society of Clinical Oncology Annual Meeting shows that a new approach to managing fevers associated with dabrafenib increases treatment tolerability and avoids discontinuation of therapy. Global Skin (International Alliance of Dermatology Patient OrganiPower of the Group: Quality of Care in AD
https://practicaldermatology.com/topics/atopic-dermatitis/power-of-the-group-quality-of-care-in-ad/19880/When researchers undertook a survey of eczema centers worldwide, they uncovered common barriers to care and identified potential solutions. Eric Simpson, MD, MCR provides on overview of the Quality of Care in Atopic Dermatitis initiative, with an emphasis on the value of the group-based analysis ofToxin Time: What’s New and Exciting with Neuromodulators
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/toxin-time-whats-new-and-exciting-with-neuromodulators/19768/Joel Cohen, MD takes a deep dive into the most recent data on neuromodulators including post-hoc analyses on the potential durability of response. Dr. Cohen also shares updates on Revance’s DAXI, Botox Cosmetic and liquid toxins under development by Galderma and Allergan.DermWireTV: Cosmetic Surgery Forum Highlights, LEO Focuses on AD
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-cosmetic-surgery-forum-highlights-leo-focuses-on-ad/19703/New treatments and medical controversies take center stage at Cosmetic Surgery Forum as the meeting moves to Nashville in its 11th Year. Leo Pharma’s tralokinumab meets all primary and secondary endpoints in three pivotal Phase 3 studies for the treatment of adults with moderate-to-severe atopic der